/ADVM
ADVM Stock - Adverum Biotechnologies, Inc.
Healthcare|BiotechnologyNASDAQ
$4.36+0.00%
+$0.00 (+0.00%) • Dec 9
72
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.78
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).72
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.85
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.8%upside
Target: $4.83
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ADVM
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$4.32 – $4.40
TARGET (TP)$4.83
STOP LOSS$4.01
RISK/REWARD1:1.3
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.87
52W High$6.07
52W Low$1.78
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $1.00M | $3.60M | N/A | $7.50M | N/A |
| Gross Profit | $1.00M | $3.60M | N/A | $7.50M | $-4,158,000 |
| Gross Margin | 100.0% | 100.0% | N/A | 100.0% | N/A |
| Operating Income | $-139,159,000 | $-128,942,000 | $-157,135,000 | $-146,122,000 | $-117,950,000 |
| Net Income | $-130,927,000 | $-122,116,000 | $-154,536,000 | $-145,540,000 | $-117,507,000 |
| Net Margin | -13092.7% | -3392.1% | N/A | -1940.5% | N/A |
| EPS | $-6.62 | $-2.02 | $-2.67 | $-1.48 | $-1.26 |
Company Overview
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
3
75%
Hold / Neutral
1
25%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
3 Bullish1 Neutral/Bearish
Price Targets
$20
Average Target
↑ 351.1% Upside
Now
$4
Low
$20
Average
$30
High
Based on 3 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 17th 2025 | H.C. Wainwright | Downgrade | Neutral | - |
| June 25th 2024 | Oppenheimer | Initiation | Outperform | $25 |
| April 30th 2024 | H.C. Wainwright | Initiation | Buy | $30 |
| July 7th 2022 | Truist | Upgrade | Buy | $4 |
Earnings History & Surprises
ADVMBeat Rate
35%
Last 20 quarters
Avg Surprise
-3.9%
EPS vs Estimate
Beats / Misses
7/13
Last 12 quarters
Latest EPS
$-2.03
Q4 2025
EPS Surprise History
Q1 24
+17.9%
$-2.30vs$-2.80
Q2 24
-17.2%
$-1.50vs$-1.28
Q3 24
+29.9%
$-0.89vs$-1.27
Q4 24
-8.3%
$-1.30vs$-1.20
Q1 25
-20.1%
$-1.57vs$-1.31
Q2 25
-8.3%
$-1.96vs$-1.81
Q3 25
-4.5%
$-2.34vs$-2.24
Q4 25
-12.8%
$-2.03vs$-1.80
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 12, 2025 | $-1.80 | $-2.03 | -12.8% | ✗ MISS |
Q3 2025 | Aug 12, 2025 | $-2.24 | $-2.34 | -4.5% | ✗ MISS |
Q2 2025 | Apr 15, 2025 | $-1.81 | $-1.96 | -8.3% | ✗ MISS |
Q1 2025 | Mar 24, 2025 | $-1.31 | $-1.57 | -20.1% | ✗ MISS |
Q4 2024 | Nov 4, 2024 | $-1.20 | $-1.30 | -8.3% | ✗ MISS |
Q3 2024 | Aug 12, 2024 | $-1.27 | $-0.89 | +29.9% | ✓ BEAT |
Q2 2024 | May 9, 2024 | $-1.28 | $-1.50 | -17.2% | ✗ MISS |
Q1 2024 | Mar 18, 2024 | $-2.80 | $-2.30 | +17.9% | ✓ BEAT |
Q4 2023 | Nov 9, 2023 | $-3.00 | $-3.30 | -10.0% | ✗ MISS |
Q3 2023 | Aug 10, 2023 | $-3.20 | $-3.10 | +3.1% | ✓ BEAT |
Q2 2023 | May 11, 2023 | $-3.00 | $-2.90 | +3.3% | ✓ BEAT |
Q1 2023 | Mar 30, 2023 | $-3.20 | $-3.30 | -3.1% | ✗ MISS |
Q4 2022 | Nov 10, 2022 | $-3.20 | $-4.00 | -25.0% | ✗ MISS |
Q3 2022 | Aug 11, 2022 | $-3.80 | $-4.40 | -15.8% | ✗ MISS |
Q2 2022 | May 12, 2022 | $-3.40 | $-3.80 | -11.8% | ✗ MISS |
Q1 2022 | Mar 29, 2022 | $-4.20 | $-3.50 | +16.7% | ✓ BEAT |
Q4 2021 | Nov 4, 2021 | $-4.20 | $-3.90 | +7.1% | ✓ BEAT |
Q3 2021 | Aug 5, 2021 | $-3.70 | $-4.50 | -21.6% | ✗ MISS |
Q2 2021 | May 6, 2021 | $-3.80 | $-2.90 | +23.7% | ✓ BEAT |
Q1 2021 | Mar 1, 2021 | $-3.20 | $-3.90 | -21.9% | ✗ MISS |
Latest News
Eli Lilly And Adverum Announce Expiration Of Tender Offer By Lilly Subsidiary To Acquire All Outstanding Adverum Shares For $3.56 Cash Plus Up To $8.91 Per Share In Contingent Value Rights, As Scheduled On December 8
📈 PositiveBenzinga•Dec 9, 2025, 01:33 PM•Also:
Adverum Urges Shareholders to Accept Eli Lilly Buyout Offering Up to $12.47 Per Share
📈 PositiveBenzinga•Dec 1, 2025, 12:26 PM•Also:
HC Wainwright & Co. Downgrades Adverum Biotechnologies to Neutral, Lowers Price Target to $5
➖ NeutralBenzinga•Nov 17, 2025, 12:02 PM
Lilly to acquire Adverum for up to $12.47 per share in cash and CVRs
📈 PositiveSeeking Alpha•Oct 24, 2025, 12:40 PM•Also:
Lilly To Acquire Adverum Biotechnologies For Total Per Share Consideration Up To $12.47; Lilly To Commence Tender Offer To Acquire All Shares For Per Share Price Of $3.56 In Cash Plus One CVR Entitling Holder To Receive Up To Additional $8/91 Per CVR In Cash Upon Milestones
📈 PositiveBenzinga•Oct 24, 2025, 12:34 PM•Also:
Trading Halt: Halted at 8:25:00 a.m. ET - Trading Halt: Halt News Pending
➖ NeutralBenzinga•Oct 24, 2025, 12:25 PM
HC Wainwright & Co. Reiterates Buy on Adverum Biotechnologies, Maintains $30 Price Target
📈 PositiveBenzinga•Sep 23, 2025, 10:53 AM
Adverum Biotechnologies Says Screening For Pivotal Phase 3 ARTEMIS Trial of Ixo-vec Closing 'Ahead Of Expectations;' Readout Accelerated To Q1 2027
📈 PositiveBenzinga•Sep 22, 2025, 12:09 PM
Frequently Asked Questions about ADVM
What is ADVM's current stock price?
Adverum Biotechnologies, Inc. (ADVM) is currently trading at $4.36 per share. The stock has moved +0.00% today.
What is the analyst price target for ADVM?
The average analyst price target for ADVM is $4.83, based on 1 analyst.
What sector is Adverum Biotechnologies, Inc. in?
Adverum Biotechnologies, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is ADVM's market cap?
Adverum Biotechnologies, Inc. has a market capitalization of $0.10 billion, making it a small-cap company.
Does ADVM pay dividends?
No, Adverum Biotechnologies, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorALXO
ALX Oncology Holdings Inc.
$1.45
Mkt Cap: $0.1B
ARTV
Artiva Biotherapeutics, Inc.
$4.74
Mkt Cap: $0.1B
ATYR
aTyr Pharma, Inc.
$0.75
Mkt Cap: $0.1B
BMEA
Biomea Fusion, Inc.
$1.40
Mkt Cap: $0.1B
DTIL
Precision BioSciences, Inc.
$4.49
Mkt Cap: $0.1B
GUTS
Fractyl Health, Inc. Common Stock
$2.20
Mkt Cap: $0.2B
MGX
Metagenomi, Inc. Common Stock
$1.76
Mkt Cap: $0.1B
PLRX
Pliant Therapeutics, Inc.
$1.23
Mkt Cap: $0.1B
QNCX
Quince Therapeutics, Inc.
$3.57
Mkt Cap: $0.2B
STRO
Sutro Biopharma, Inc.
$9.98
Mkt Cap: $0.1B
Explore stocks similar to ADVM for comparison